Tscan Therapeutics Stock Filter Stocks by Fundamentals
| TCRX Stock | USD 1.82 0.07 3.70% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Tscan Therapeutics' long-term financial health and intrinsic value.
Tscan | Shares Owned by Institutions | Build AI portfolio with Tscan Stock |
Tscan Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Tscan Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Tscan Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tscan Therapeutics' value.| Shares | State Street Corp | 2025-03-31 | 817.2 K | Ecor1 Capital, Llc | 2025-03-31 | 662.8 K | Dc Funds, Lp | 2025-03-31 | 630 K | Tang Capital Management Llc | 2025-03-31 | 600 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 593 K | Northern Trust Corp | 2025-03-31 | 330 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 270.1 K | Jpmorgan Chase & Co | 2025-03-31 | 265.1 K | Millennium Management Llc | 2025-03-31 | 231.2 K | Bvf Inc | 2025-03-31 | 4.9 M | Blackrock Inc | 2025-03-31 | 4.9 M |
Tscan Fundamentals
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (16.70) % | ||||
| Current Valuation | (47.7 M) | ||||
| Shares Outstanding | 52.31 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 88.07 % | ||||
| Number Of Shares Shorted | 1.98 M | ||||
| Price To Earning | 23.45 X | ||||
| Price To Book | 0.51 X | ||||
| Price To Sales | 24.19 X | ||||
| Revenue | 2.82 M | ||||
| Gross Profit | (5.36 M) | ||||
| EBITDA | (119.74 M) | ||||
| Net Income | (127.5 M) | ||||
| Cash And Equivalents | 125.6 M | ||||
| Cash Per Share | 5.22 X | ||||
| Total Debt | 97.38 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 3.71 X | ||||
| Cash Flow From Operations | (110.82 M) | ||||
| Short Ratio | 2.95 X | ||||
| Earnings Per Share | (1.08) X | ||||
| Target Price | 9.0 | ||||
| Number Of Employees | 200 | ||||
| Beta | 0.98 | ||||
| Market Capitalization | 102.43 M | ||||
| Total Asset | 371.12 M | ||||
| Retained Earnings | (375.1 M) | ||||
| Working Capital | 256.77 M | ||||
| Net Asset | 371.12 M |
About Tscan Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tscan Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tscan Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tscan Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.